**Table e-1.** Demographic and clinical characteristics of patients with high and low disability progression belonging to the discovery cohort.

|  |  |  |
| --- | --- | --- |
| Characteristics | Numeric progression rates “onset”1 | Step-based progression rates “onset”1 |
|  | High / Low | High / Low |
| n | 7 / 21 | 7 / 21 |
| Age (years) | 47.0 (10.3) / 49.8 (9.2) | 46.4 (10.1) / 50.0 (9.2) |
| % women | 42.9 / 42.9 | 28.6 / 47.6 |
| % PP | 57.1 / 61.9 | 42.9 / 66.7 |
| Follow-up time (years)2 | 9.3 (5.4) / 13.6 (3.7) | 8.6 (5.2) / 13.9 (3.4) |
| EDSS onset3  | 4.0 (4.0-6.0) / 6.0 (4.5-6.0)  | 6.0 (4.0-6.0) / 6.0 (4.0-6.0)  |
| EDSS last3 | 8.5 (8.0-9.5) / 7.0 (6.5-8.5)  | 9.0 (8.5-9.5) / 7.0 (6.5-8.5)  |
| % treated with IFNβ4 | 43.0 / 47.6  | 28.6 / 52.4  |

#### All data are expressed as mean (standard deviation) unless otherwise stated. EDSS is expressed as median (interquartile range). 1Refers to numeric and step-based progression rates calculated from trial onset. 2Refers to time from trial onset to the last visit. 3Refers to EDSS at trial onset and at the time of last visit. 4Refers to % of patients under IFNβ treatment at the time of CSF collection. EDSS: Expanded Disability Status Scale. IFNβ: interferon beta-1b. %PP: refers to the % of patients with primary progressive MS.